MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
28 Mai 2009 - 8:00AM
PR Newswire (US)
Site to Provide Glucotrace (Fluorodeoxyglucose) for Use in Earlier
Detection of Disease and Therapy Management OTTAWA and FLEURUS,
Belgium, May 28 /PRNewswire-FirstCall/ -- MDS Nordion, a leading
global provider of medical isotopes and radiopharmaceuticals used
in molecular medicine, today announced the opening of a facility in
Fleurus, Belgium for the production of Glucotrace
(Fluorodeoxyglucose), a radiopharmaceutical used in positron
emission tomography (PET) imaging. PET imaging produces a
three-dimensional image, or picture, of functional processes in the
body, such as brain activity, and is a highly accurate and
effective method of diagnosing disease and managing patient
therapy. MDS Nordion's new facility will provide timely supply of
Glucotrace to hospitals throughout Belgium, France, The
Netherlands, Luxembourg and Germany. "Customers count on MDS
Nordion for leadership, quality products and customized services,"
said Steve West, President MDS Nordion. "Our investment in this
facility further demonstrates our commitment to address the growing
demand for PET diagnostic imaging in targeted European regions, and
provides the medical community greater service for their future
patient care." The PET imaging market is the most rapidly growing
area of nuclear medicine and procedures. Statistics from a recent
Medical Options survey indicates PET examinations are on a rapid
rise in Europe, and are expected to grow at a compound annual rate
of approximately 20% through 2012. To help meet increasing demand,
this state-of-the-art, Good Manufacturing Practice (GMP) production
facility will have three daily production runs and a customer
service team available 24 hours a day, seven days a week. "PET
imaging is effective because it allows early detection of tumours,
as well as assessment of therapeutic strategies," said Professor
Roland Hustinx, Nuclear Medicine Department, CHU - Universite de
Liege. "In particular, MDS Nordion's new facility will provide
another source of supply of Glucotrace to existing and new medical
facilities, thereby increasing the ability of health-care
practitioners to conduct this critical type of imaging." About MDS
Nordion MDS Nordion, a business unit of MDS Inc., is a global
leader in providing medical isotopes for molecular and diagnostic
imaging, radiotherapeutics and sterilization technologies for
medical products that benefit the lives of millions of people in
more than 50 countries around the world. MDS Nordion's products and
services are used on a daily basis by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Find out more at
http://www.mdsnordion.com/. About MDS MDS Inc. (TSX: MDS; NYSE:
MDZ) is a global life sciences company that provides market-leading
products and services that our customers need for the development
of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research,
medical isotopes for molecular imaging, radiotherapeutics, and
analytical instruments. MDS has more than 5,000 highly skilled
people in 29 countries. Find out more at http://www.mdsinc.com/.
DATASOURCE: MDS Nordion CONTACT: CONTACT MDS Nordion: MEDIA:
Shelley Maclean, (613) 291-3689, ; INVESTORS: Kim Lee, (416)
213-4721,
Copyright